Heidelberg Pharma AG
HPHA
Company Profile
Business description
Heidelberg Pharma AG is a biopharmaceutical company. It is focused on oncology and develops the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform and advances the biological mode of action of the toxin as a novel therapeutic principle. The proprietary lead candidate is HDP-101 which is a BCMA (B-cell maturation antigen) - ATAC for multiple myeloma. In addition, the company offers preclinical contract research services. It operates through the following business divisions: Customer Specific Research, Diagnostics, and TherapeuticS.
Contact
Gregor-Mendel-Street 22
Ladenburg68526
DEUT: +49 620310090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 November 2025
Employees
122
Stocks News & Analysis
stocks
Is this the $80 billion elephant Warren Buffett has been waiting for?
Morningstar’s Greg Warren says Berkshire may have little choice but to take a hard look at this huge potential acquisition.
stocks
Tesla: Board announces new pay package for CEO Elon Musk
A key provision of the new award is that Musk must remain in a senior leadership position at Tesla.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,005.80 | 83.80 | 0.94% |
| CAC 40 | 7,632.01 | 85.85 | 1.14% |
| DAX 40 | 23,757.69 | 331.72 | 1.42% |
| Dow JONES (US) | 44,173.64 | 585.06 | 1.34% |
| FTSE 100 | 9,128.30 | 59.72 | 0.66% |
| HKSE | 24,757.99 | 24.54 | 0.10% |
| NASDAQ | 21,053.58 | 403.45 | 1.95% |
| Nikkei 225 | 40,544.99 | 254.29 | 0.63% |
| NZX 50 Index | 12,813.65 | 129.61 | 1.02% |
| S&P 500 | 6,329.94 | 91.93 | 1.47% |
| S&P/ASX 200 | 8,745.50 | 81.80 | 0.94% |
| SSE Composite Index | 3,599.41 | 16.10 | 0.45% |